Michael S. Gordon - 25 Jul 2025 Form 4/A - Amendment Insider Report for ProMIS Neurosciences Inc. (PMN)

Reporting relationship: Other*
Issuer ticker: PMN
Reported as of: 25 Jul 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 14 Aug 2025, 16:17:09 UTC
Original report date: 29 Jul 2025
Prior SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael S. Gordon

Key filing fact

Michael S. Gordon filed Form 4/A - Amendment for ProMIS Neurosciences Inc. (PMN) on 14 Aug 2025.

Key facts

This page summarizes Michael S. Gordon's Form 4/A - Amendment filing for ProMIS Neurosciences Inc. (PMN).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 16:17.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001034608 Primary reporting owner

GORDON MICHAEL S

Relationship: Other*
Address: C/O TROVE,, 40 BROAD STREET, 8TH FLOOR, BOSTON
Signature: /s/ Michael S. Gordon
Signature date: 14 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMN transaction Derivative

Tranche A Common Share Purchase Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -119,800
Change %: -26%
Price: $0.000000
Shares after: 345,316
Date: 25 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 119,800
Exercise price
Footnotes: F1, F2, F3

PMN transaction Derivative

Tranche B Common Share Purchase Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -119,800
Change %: -26%
Price: $0.000000
Shares after: 345,316
Date: 25 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 119,800
Exercise price
Footnotes: F2, F3, F4

PMN transaction Derivative

Tranche C Common Share Purchase Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -119,800
Change %: -26%
Price: $0.000000
Shares after: 345,316
Date: 25 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 119,800
Exercise price
Footnotes: F2, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

Footnote F2

This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

Footnote F3

By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

Footnote F4

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

Footnote F5

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

SEC remarks

The Issuer's Form 10-Q filed on August 13, 2025 provides that as of such date, the Issuer had 51,806,497 Common Shares outstanding. Based on this number and other shares included in the denominator of the calculation of the Reporting Person's ownership, the Reporting Person's ownership has dropped below 10% as of the date of filing this amended Form 4. However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was originally filed, the Reporting Person held more than 10% at such time the Form 4 was originally filed.